Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation
Positive Non-small Cell Lung Cancer
Basic Study Information
Purpose:Location: University of Rochester
This phase II trial studies how well trametinib and docetaxel work in treating patients
stage IV KRAS mutation positive non-small cell lung cancer or cancer that has come
Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed
growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop
growth of tumor cells, either by killing the cells, by stopping them from dividing,
stopping them from spreading. Giving trametinib with docetaxel may work better in
non-small cell lung cancer.
Study Contact Information
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search